Advertisement
VANCOUVER, BRITISH COLUMBIA, Jan. 08, 2019 /PRNewswire-PRWeb/ -- Carolyn Cross, Chairman and Chief Executive Officer of Ondine Biomedical Inc., was appointed to Canada's
National Research Council (NRC) for a second term. As a founder of Ondine Biomedical Inc., Carolyn is a seasoned MedTech entrepreneur with a passion for promoting Canadian innovation, small Canadian business enterprises and advancing women in business. The National Research Council is the Government of Canada's largest research organization supporting industrial innovation, the advancement of knowledge and technology development, and fulfilling government mandates.
About Ondine Biomedical Inc. Ondine Biomedical Inc. is dedicated to the development of non-antibiotic, anti-infective therapies for a broad-spectrum of bacterial, viral and fungal infections. Ondine's antimicrobial program utilizes a platform technology called photodisinfection, a light-activated approach being developed to provide rapid antimicrobial efficacy and reduced risk of antibiotic resistance. Over 70 patents in 21 patent families have been granted or are pending covering various aspects of the technology. Ondine's flagship nasal photodisinfection system, Steriwave™ ND, has been deployed in Canada for several years under the brand MRSAid™. Other applications of the photodisinfection platform are under development, including Sinuwave™, a photodisinfection product to treat chronic rhinosinusitis, and an endotracheal tube photodisinfection product designed to reduce the incidence of ventilator-associated pneumonia (VAP).
Contact Ondine Biomedical Inc. Angelika Vance, Director – Corporate Development [email protected]
SOURCE Ondine Biomedical, Inc.
Advertisement
About Ondine Biomedical Inc. Ondine Biomedical Inc. is dedicated to the development of non-antibiotic, anti-infective therapies for a broad-spectrum of bacterial, viral and fungal infections. Ondine's antimicrobial program utilizes a platform technology called photodisinfection, a light-activated approach being developed to provide rapid antimicrobial efficacy and reduced risk of antibiotic resistance. Over 70 patents in 21 patent families have been granted or are pending covering various aspects of the technology. Ondine's flagship nasal photodisinfection system, Steriwave™ ND, has been deployed in Canada for several years under the brand MRSAid™. Other applications of the photodisinfection platform are under development, including Sinuwave™, a photodisinfection product to treat chronic rhinosinusitis, and an endotracheal tube photodisinfection product designed to reduce the incidence of ventilator-associated pneumonia (VAP).
Contact Ondine Biomedical Inc. Angelika Vance, Director – Corporate Development [email protected]
SOURCE Ondine Biomedical, Inc.
